Introduction
Ovarian cancer is the fifth leading cause of cancer death among women in the United States, with an estimated 22 220 new cases and 16 210 deaths expected in 2005. 1 Women with early stage disease combined with favorable prognostic factors have a 490% cure rate with surgery alone. 2 However, as a result of a lack of symptoms in early stages of the disease, the majority of patients are diagnosed with stage III/IV disease and have a 5-year-survival of o30%. 3 Standard therapy for advanced ovarian cancer involves debulking surgery followed by chemotherapy with carboplatin/paclitaxel. 4 Apoptosis plays a major role in chemotherapy-induced tumor cell death, and progression of ovarian cancer appears to favor the development and selection of cells that are resistant to apoptotic triggers. Many factors have been implicated in this failure of apoptosis and consequent chemotherapy resistance, for example p53 mutations and increased Bcl-2 expression. 5, 6 Drug resistance has also been related to mechanisms such as alterations in drug transport and metabolism, and cellular DNA repair systems. 7 So, while current therapies may be initially effective, many tumors ultimately become chemoresistant, resulting in treatment failure. Consequently, there remains an urgent need for novel therapeutic approaches to ovarian cancer treatment.
Imaging and therapy of thyroid disease is made possible as a result of the ability of the thyroid to accumulate iodide. This is mediated by the sodium iodide symporter (NIS), a transmembrane glycoprotein expressed at the basolateral membrane of thyroid follicular cells. 8 Recent developments in gene therapy have led to a number of studies aimed at introducing NIS expression in other tumor types, to provide for radioiodide imaging and therapy. [9] [10] [11] [12] [13] [14] [15] [16] The ability to introduce NIS expression into ovarian tumors would be highly beneficial. Along with an extended proven record in radioiodide therapy of thyroid disease, NIS offers a major advantage as a therapeutic gene because it provides for imaging to confirm targeted expression of the protein before proceeding to therapy. Also, the bystander effect associated with the use of 131 I means that all of the target cells do not need to express NIS for a complete therapeutic effect to be seen. 12 We have previously reported the successful use of the MUC1 promoter to drive NIS expression for radioiodide imaging and therapy of breast cancer cells.
17 MUC1 overexpression has also been reported in the majority of ovarian tumors, [18] [19] [20] [21] and so this construct has potential for application in this tumor model. This study describes the introduction of NIS expression into ovarian tumor cells both in vitro and in vivo, followed by 123 I imaging and 131 I therapy. Ovarian tumors present an extra challenge for virusmediated gene therapy as they have been shown to express variable levels of the molecules required for adenoviral infection, such as the coxsackievirus and adenovirus receptor (CAR), and integrins. 22 For this reason, two adenoviral constructs containing NIS under the control of the (1) cytomegalovirus (CMV) or (2) MUC1 promoters were used to infect an ovarian cancer cell line (OVCAR-3), which had been reported to express moderate levels of CAR. 23 The potent nonspecific CMV promoter was initially used to determine whether functional NIS expression could be established in this model in vivo. Following successful therapy of CMV/ NIS-transduced tumors, the MUC1/NIS construct was used to provide transcriptional targeting to the MUC1-positive tumors and further reduce the risk of extratumoral toxicity. 24 This study represents a promising first step investigating the potential for NIS-mediated radioiodide imaging and therapy of ovarian tumors.
Results

I uptake studies
The ability of OVCAR-3 cells to take up iodide at various time points following infection with Ad/CMV/NIS or Ad/MUC1/NIS was investigated in vitro ( Figure 1 ). Optimal iodide uptake was seen 3 days following infection, with a 12-fold increase over control cells observed in CMV/NIS-transduced cells (42267169 c.p.m.), compared to a 5.5-fold increase in MUC1/NIS-transduced cells (1898723 c.p.m). In all cases, iodide uptake was blocked in the presence of KCLO 4 , a known inhibitor of NIS function.
Western blot
Membrane protein extracts (10 mg) from NIS-transduced ovarian cancer (OVCAR-3) cells were subjected to Western blot with a mouse monoclonal antibody directed against amino-acids 468-643 of the human NIS protein (Figure 2 ). Membrane extracts from cells that had been infected with both CMV/NIS (Figure 2a (ii)) and MUC1/ NIS (Figure 2b (ii)) were positive for the NIS protein, at the expected size of B75-100 kDa. The size of the NIS protein is dependent upon glycosylation status, and can range from 50 to 110 kDa, with 50 kDa representing the unglycosylated protein. The level of immunoreactivity detected in the CMV/NIS-transduced cells was stronger than that observed when NIS was under the control of the MUC1 promoter, although this cell line does express high levels of the MUC1 protein. There was no NIS protein detected in cells that had been infected with control virus (Figure 2a In order to be functional, the NIS protein must be targeted to the cell membrane. 8 When under the control of the CMV promoter, NIS appeared to have improved membrane targeting, which correlated with the increased levels of iodide uptake observed in Figure 1 . Cells infected with a promoterless virus were negative for NIS immunoreactivity (Figure 3a) . 
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In vivo
I imaging
Mice with OVCAR-3 tumor xenografts 4100 mm 3 were given intratumoral injections of Ad/CMV/NIS, followed 3 days later by intraperitoneal administration of 0.5 mCi 123 I. Images were then acquired on a g-camera at a series of time points 1-48 h after iodide administration ( Figure  4 ). Initial images did not show strong uptake at the site of the tumors (results not shown), and so the experiment was repeated following drainage of ascitic fluid, to increase virus delivery to tumor tissue. Results are shown in Figure 4 . Iodide uptake can be seen in all images at the site of the thyroid and stomach, which express NIS, and at the site of the bladder where iodide is being excreted. Iodide uptake in the stomach is not routinely observed in nuclear scans of patients undergoing iodide therapy, and gastric toxicity is not a reported side effect of radioiodide therapy. 25, 26 The strong stomach image seen here may be as a result of increased NIS expression in the murine gastric mucosa. The image of the bladder is as a result of clearance of radioiodide in the urine, rather than expression of NIS, and is seen even in the absence of virus injection (not shown). Figure 4c shows a mouse bearing a left flank tumor that had been injected with the promoterless virus (Ad/ NIS), and no iodide uptake at the tumor site is observed.
I therapy
Mice received an intratumoral injection of 5 Â 10 8 PFU of Ad/CMV/NIS, Ad/MUC1/NIS or Ad/CMV, followed 3 days later by an intraperitoneal dose of either 3mCi 131 I or saline. Tumor size (L ÂW Â H Â 0.51) was then measured on a weekly basis using calipers ( Figure 5 ).
Tumors that had been injected with CMV/NIS followed by 131 I therapy gradually decreased in size, to o50% of their starting volume by week 8. At this same I. At 3 days before iodide administration, the mice were given intratumoral injections of Ad/CMV/NIS, Ad/MUC1/NIS or control virus. All three images show iodide uptake in the thyroid and stomach, which both express NIS, and in the bladder where iodide was being cleared in the urine. Image (a) also reveales a clear image of the tumor that had been infected with Ad/CMV/NIS on the left flank with a less intense tumor image apparent in the animal that had been injected with the MUC1/NIS construct (b). In panel (c), where the left flank tumor had been infected with control virus, there is no tumor image.
NIS-
time point, tumors that had been injected with CMV/ NIS followed by saline, or control virus followed by 131 I, had dramatically increased in size to a mean volume of 268735 and 3327154% of starting volume, respectively (Po0.0001). There was a large standard error for the control group treated with saline as a result of extremely fast tumor growth in one of the animals at weeks 7/8, with volume increasing from 380 to 627% of starting volume within 7 days. In animals that had received intratumoral injections of MUC1/NIS, the tumors did not regress, but the tumor size was significantly smaller (166732% at 8 weeks) than tumors in control animals (Po0.05).
Discussion
This study describes the successful introduction of NIS expression into ovarian tumor xenografts in nude mice, followed by radioiodide imaging and therapy. Native NIS expression in ovarian tumors has been detected by immunohistochemistry, but was reported to be weak and confined to the cytoplasm, where it would not be functional. 27 Although NIS gene transfer into ovarian cells in vitro has been reported previously, 15, 28 this is the first study to report NIS-mediated 131 I therapy of ovarian tumors in an animal model.
The ability of the virus to enter the cells is a major ratelimiting factor for the efficacy of gene therapy. Ovarian tumors have been shown to be heterogeneous for expression of the molecules involved in virus attachment and infection, such as CAR and integrins. 22 The OVCAR-3 cell line used here expresses moderate levels of CAR. 23 In vitro infections followed by immunostaining for NIS revealed patchy positive staining that was both intracellular and membrane bound. The NIS protein must be targeted to the cell membrane to be functional. 8 When under the control of the CMV promoter, NIS was correctly targeted to the cell membrane, which correlated with relatively high levels of iodide uptake. Initial in vivo radioiodide imaging of ovarian tumor xenografts in mice did not reflect the promising iodide uptake/NIS expression levels seen in vitro. This may have been as a result of the cystic nature of the ovarian tumors, as the presence of ascites made it more challenging to inject virus directly into tumor tissue. In consequent experiments, the ascitic fluid was drained from the tumors prior to virus injection. This resulted in more robust 123 I tumor imaging in vivo, and reduction of CMV/NIS-transduced tumor size following 131 I therapy. This highlights the fact that, as a result of the bystander effect of radioiodide therapy, all of the cells do not need to express NIS for a therapeutic effect to be seen. 12 Although tumors regressed to less than 47% of their starting volume by 8 weeks following therapy, extended monitoring did reveal tumor regrowth. Despite this, at 14 weeks following therapy, the tumors were still less than 70% of their original volume, compared to control tumors, which had almost tripled in size. The therapeutic results seen here are not as dramatic as those observed in previous studies of prostate and breast cancer animal models. 9, 17 The fact that drainage of ascitic fluid improved initial results suggests that intratumoral delivery of virus may be more suitable for solid tumor models.
Although these preliminary results are somewhat promising for the use of NIS-mediated therapy of ovarian tumors, the lack of specificity conferred by the CMV promoter may be problematic. Most ovarian cancers are detected only after they have metastasized, and so consist of multiple disseminated tumors, often confined to the peritoneal cavity.
2 Therefore, intraperitoneal administration of virus is an attractive route for therapy of this disease to increase virus/tumor cell interaction, but this does raise selectivity concerns. Noninvasive radioiodide imaging can be performed to confirm correct localization of NIS before proceeding to therapy. However, transcriptional targeting of NIS expression could potentially increase the viral dose to the target cells, and avoid toxicity to the liver and normal mesothelial cells.
We recently reported complete tumor regression following Ad5/MUC1/NIS-mediated therapy of breast cancer xenografts in mice. 17 The vast majority of ovarian tumors have also been reported to overexpress MUC1, [18] [19] [20] [21] while it is weakly or not at all expressed by normal mesothelial cells. 29 Following the success of the CMV/ NIS construct, we proceeded to use Ad/MUC1/NIS to provide transcriptional targeting to the tumors and minimize potential effects on surrounding normal cells. 30 In the current model, despite the fact that OVCAR-3 cells express robust MUC1 protein, 18 the levels of NIS expression were not high enough to cause tumor regression following 131 I therapy. This may be as a result of reduced infection efficiency when compared to the breast cancer model.
123
I imaging revealed limited iodide uptake at the tumor site. However, at the 8-week time point, tumor volume was significantly smaller following MUC1/NIS infection and 131 I therapy, compared to control tumors. This suggests that with improvements that result in higher expression levels, this may be a viable approach for this tumor model. 
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Success of adenovirus-mediated gene transfer is dependent upon efficient in vivo transduction. The inclusion of an enhancer element upstream of the MUC1 promoter may increase the level of NIS expression obtained, 31 but would not overcome suboptimal tumor transduction rates. Many groups have shown improved infection of CAR-deplete ovarian cancer models using CAR-independent or tropism-modified adenoviral constructs to circumvent the liver and target specific cell types that are normally refractory to adenoviral infection. [32] [33] [34] [35] This could increase the viral load at the tumor site and permit use of lower viral doses, potentially reducing the immune response following virus administration.
The promising preliminary results presented here showing radioiodide imaging and therapy of ovarian tumors, combined with the generation of modified adenoviral vectors, suggest potential for NIS-mediated therapy as a novel approach to ovarian cancer treatment.
Materials and methods
Cell culture
The ovarian cancer cell line OVCAR-3 was maintained in RPMI media, supplemented with 10% fetal bovine serum and penicillin G (2 U/ml)/streptomycin sulfate (100 mg/ml). Cells were maintained at 371C, 5% CO 2 with a media change twice weekly and passage every 7 days.
Adenovirus production
A replication-deficient human recombinant adenovirus serotype 5 construct containing human NIS under the control of the MUC1 promoter (À1401 to +33) was produced in collaboration with ViraQuest Inc. (North Liberty, IA, USA) as described previously. 17 Briefly, the MUC1/NIS insert was cloned into a VQ/5k plasmid shuttle vector provided by ViraQuest, and then transfected into 293 cells containing adenoviral DNA that had previously been restricted to remove a portion of the E1 region. Following plaque purification, the recombinant adenovirus Ad/MUC1/NIS was expanded in 293 cells and purified by banding on CsCl density gradients, followed by dialysis. Another replicationdeficient adenovirus containing NIS under the control of the non-specific CMV promoter was in stock from previous experiments and had been created using the same technique. 16 
Adenoviral infection of OVCAR-3 cells
Cells were plated into 12-well plates the day before infection at a seeding density of 1.5 Â 10 5 cells/well, to reach B60% confluence for infection. Cells were then washed and incubated in serum-free medium and varying quantities of virus added to each well. Following a 3 h incubation at 371C, cells were washed and incubated in complete medium for 72 h before analysis of NIS expression/function. All adenoviral infections were carried out at least in triplicate.
I uptake studies
The ability of the cells to concentrate iodide was determined as described by Weiss et al. 36 Briefly, following transfection, cells were incubated in HBSS containing 10 mM HEPES, 10 mM NaI and 0.1 mCi of Na 125 I/ml, pH 7.3, and 10 mM KClO 4 , a competitive inhibitor of iodide uptake by NIS, was included in control wells. Following a 45-min incubation at 371C, cells were washed with ice-cold phosphate-buffered saline (PBS), lysed with 1 M NaOH, and concentrated iodide was measured on a g-counter.
Membrane extraction
Membrane proteins were extracted from infected cells using a previously described procedure. 37 Briefly, cells were washed and resuspended in buffer A (250 mM sucrose, 10 mM HEPES (pH 7.5), 1 mM EDTA, 10 mg/ml leupeptin, 2 mg/ml aprotinin, 1 mM PMSF) and then frozen overnight at À201C. The cell suspension was then thawed and centrifuged at 500 g for 15 min at 41C. A 1 ml portion of 1 M Na 2 CO 3 was added per ml of supernatant followed by 45 min shaking at 41C. The solution was then centrifuged at 100 000 g for 15 min and the pellet resuspended in buffer B (250 mM sucrose, 10 mM HEPES (pH 7.5), 1 mM MgCl 2 ). The protein content was determined using the BioRad DC Protein Assay (Hercules, CA, USA).
Western blot analysis
The NuPAGE electrophoresis system (Invitrogen, Carlsbad, CA, USA) was used for Western blot analysis. Membrane protein from cell lines (10 mg) was reduced in DTT (0.5 M) for 10 min at 701C. Samples were then run on a 4-12% gradient precast NuPAGE Bis-Tris polyacrylamide gel for 1 h at 200 V. Aliquots of protein molecular weight standards were run simultaneously on each gel for comparison of sample protein size. Electroblotting was performed for 1 h at 25 V to transfer protein samples to a nitrocellulose membrane. To prevent nonspecific binding, membranes were incubated in 5% milk in TBS-T (20 mM Tris, 137 mM NaCl, 0.1% Tween 20) for 1 h, followed by washing in TBS-T. Membranes were incubated in a mouse monoclonal antibody (1:20 000 in 0.1% milk) directed against the human NIS protein (aa 468-643) 38 for 1.5 h and washed in TBS-T. Horseradish peroxidase-labeled goat anti-mouse antibody (1:10 000) was then added to the membranes for 1.5 h. Following washing steps, ECL Western Blotting Detection Reagents (Amersham, Arlington Heights, IL, USA) were applied to the membranes for 1 min. Kodak BIOMAX MR films were then exposed to the membranes for approximately 2 min.
Immunohistochemical analysis
Cells were plated into two-chamber slides at a seeding density of 1.5 Â 10 5 /well before infection and immunohistochemistry. Slides were put on ice for 15 min and then cells were fixed in cold methanol at À201C for 15 min. Following methanol removal, cells were incubated in 10% normal goat serum (NGS) diluted in PBS/ 0.05% Tween 20 (PBS-T) for 30 min to block nonspecific binding. A mouse monoclonal antibody (1:2000) directed against the human NIS protein (aa 468-643) 38 was then applied for 60 min followed by washing in PBS-T. Cells were then incubated with a biotinylated goat anti-mouse immunoglobulin (1:200) for 20 min. Cells were washed and then peroxidase-conjugated streptavidin (1:300) was applied for 20 min. Following washing, detection was carried out using a peroxidase substrate kit containing NIS-mediated radioiodide therapy for ovarian cancer RM Dwyer et al the chromogen diaminobenzidine (DAB) (Vector Laboratories, Burlingame, CA, USA). Cells were counterstained with malachite green for 5 min before mounting using Dako s Glycergel mounting medium (Carpintoria, CA, USA).
Growth of ovarian cancer xenografts in mice
Female athymic nude mice (Harlan Sprague-Dawley, Indianapolis, IN, USA) received a subcutaneous injection of 1 Â 10 6 OVCAR-3 cells suspended in 0.2 ml RPMI medium in one or both flanks. When tumors had reached an appropriate volume (X100 mm 3 ), mice were placed on a low-iodine diet with T 4 -supplemented water (5 mg/l) to reduce thyroidal uptake of iodide. All experiments were approved and carried out according to the guidelines of the Animal Care and Use Committee of the Mayo Clinic (Rochester, MN, USA).
Adenoviral infection of tumor xenografts
Mice with tumors X100 mm 3 that had been maintained on the low-iodide diet were given intratumoral injections of 5 Â 10 8 PFU of recombinant Ad5-CMV-NIS, Ad5-MUC1-NIS, or control virus in a total volume of 100 ml of 3% sucrose/PBS. Tumors were injected at multiple sites to increase virus dispersal, using insulin syringes. If necessary, tumors were aspirated in an attempt to remove ascitic fluid before virus injection.
In vivo tumor imaging
At 3 days following injection of virus into the OVCAR-3 tumors, mice were given an intraperitoneal injection of 0.5 mCi 123 I and images were acquired on a gamma camera with a low-energy, high-resolution collimator. Serial images were acquired at various time points from 1 to 48 h following iodide administration.
I therapy
Mice were grouped according to the size of the OVCAR-3 tumors and given intratumoral injections of Ad5-CMV-NIS, Ad5-MUC1-NIS or control virus as described above. At 3 days following virus administration, mice were given an intraperitoneal injection of either 3 mCi 131 I or saline (control group). The volume of the NIS-transduced and control tumors was monitored and compared on a weekly basis following administration of the iodide, in both groups treated with 131 I and those given saline. Statistical analysis was performed using the Student's t-test (unpaired). Statistical significance was indicated by a P-value of p0.05.
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